GlassScriptPhysician profile
Douglas L Bradley
NPI 1689669301
$2,671.28
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,309 · 2020: $714 · 2021: $618 · 2022: $30.14.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.82 | 2019-2021 | |
| Novo Nordisk INC | $248.69 | 2019-2021 | |
| Pfizer INC. | $239.47 | 2019-2022 | |
| Lilly USA, LLC | $230.54 | 2019-2021 | |
| Abbvie INC. | $218.92 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $199.60 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $118.88 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $118.55 | 2019-2020 | |
| Glaxosmithkline, LLC. | $108.85 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.60 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.32 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $81.44 | 2019-2020 | |
| Astellas Pharma US INC | $81.07 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $69.43 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $67.35 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $58.31 | 2019 | |
| Amgen INC. | $50.78 | 2019-2021 | |
| Esperion Therapeutics, INC. | $42.36 | 2020-2021 | |
| Angiodynamics, INC. | $37.58 | 2019 | |
| Eisai INC. | $36.58 | 2020 | |
| Allergan, INC. | $32.23 | 2020 | |
| Dexcom, INC. | $30.90 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $29.12 | 2019 | |
| Mylan Specialty L.P. | $26.44 | 2019 | |
| Adlon Therapeutics L.P. | $23.24 | 2020 | |
| Upsher-Smith Laboratories LLC | $19.17 | 2020 | |
| Shire North American Group INC | $18.41 | 2019 | |
| Almatica Pharma LLC | $15.49 | 2021 | |
| Boston Scientific Corporation | $13.14 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Bradley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.